泰利他赛普治疗系统性红斑狼疮的有效性和安全性:一项回顾性现实研究。

IF 1.9 4区 医学 Q3 RHEUMATOLOGY
Lupus Pub Date : 2025-05-01 Epub Date: 2025-04-20 DOI:10.1177/09612033251332052
Jing Zhang, Yue Sun, Na Zhang, Li-Hua Chang, Lei Jin, Yun Guo
{"title":"泰利他赛普治疗系统性红斑狼疮的有效性和安全性:一项回顾性现实研究。","authors":"Jing Zhang, Yue Sun, Na Zhang, Li-Hua Chang, Lei Jin, Yun Guo","doi":"10.1177/09612033251332052","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesTo assess the real-world efficacy and safety of telitacicept in Chinese systemic lupus erythematosus (SLE) patients.MethodsThis retrospective single-center observational study enrolled 41 SLE patients treated with telitacicept between April 2021 and March 2022. Baseline characteristics and 24-week follow-up clinical outcomes were collected for analysis.ResultsA total of 41 SLE patients who received telitacicept at least once were included. Compared with baseline (10.0 ± 6.85), SLEDAI-2K scores significantly decreased at 12 weeks (6.25 ± 5.46, <i>p</i> < .001) and 24 weeks (4.18 ± 4.78, <i>p</i> < .001). The proportion of organ involvement, as assessed by SLEDAI-2K, significantly decreased in skin/mucosa and musculoskeletal involvement. The mean glucocorticoid dose (prednisone equivalent) was significantly reduced at 12 weeks (14.19 ± 8.88 mg/d, <i>p</i> < .001) and 24 weeks (9.86 ± 4.25 mg/d, <i>p</i> = .001) compared with baseline (20.87 ± 16.71 mg/d). C3 and C4 levels showed an increasing trend. In patients with lupus nephritis, 24-h urinary protein levels significantly reduced from 2.81 ± 3.83 g/day at baseline to 1.00 ± 1.32 g/day after 24 weeks of treatment (<i>p</i> = .005), with a 68.66% decline (IQR, 35.61%, 76.30%). Albumin levels also significantly improved (<i>p</i> = .003). Nine treatment-emergent adverse events (TEAEs) were recorded in six patients, all of which were mild and moderate.ConclusionsIn this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":"34 6","pages":"597-607"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010050/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.\",\"authors\":\"Jing Zhang, Yue Sun, Na Zhang, Li-Hua Chang, Lei Jin, Yun Guo\",\"doi\":\"10.1177/09612033251332052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectivesTo assess the real-world efficacy and safety of telitacicept in Chinese systemic lupus erythematosus (SLE) patients.MethodsThis retrospective single-center observational study enrolled 41 SLE patients treated with telitacicept between April 2021 and March 2022. Baseline characteristics and 24-week follow-up clinical outcomes were collected for analysis.ResultsA total of 41 SLE patients who received telitacicept at least once were included. Compared with baseline (10.0 ± 6.85), SLEDAI-2K scores significantly decreased at 12 weeks (6.25 ± 5.46, <i>p</i> < .001) and 24 weeks (4.18 ± 4.78, <i>p</i> < .001). The proportion of organ involvement, as assessed by SLEDAI-2K, significantly decreased in skin/mucosa and musculoskeletal involvement. The mean glucocorticoid dose (prednisone equivalent) was significantly reduced at 12 weeks (14.19 ± 8.88 mg/d, <i>p</i> < .001) and 24 weeks (9.86 ± 4.25 mg/d, <i>p</i> = .001) compared with baseline (20.87 ± 16.71 mg/d). C3 and C4 levels showed an increasing trend. In patients with lupus nephritis, 24-h urinary protein levels significantly reduced from 2.81 ± 3.83 g/day at baseline to 1.00 ± 1.32 g/day after 24 weeks of treatment (<i>p</i> = .005), with a 68.66% decline (IQR, 35.61%, 76.30%). Albumin levels also significantly improved (<i>p</i> = .003). Nine treatment-emergent adverse events (TEAEs) were recorded in six patients, all of which were mild and moderate.ConclusionsIn this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients.</p>\",\"PeriodicalId\":18044,\"journal\":{\"name\":\"Lupus\",\"volume\":\"34 6\",\"pages\":\"597-607\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010050/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lupus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09612033251332052\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lupus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09612033251332052","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的评价泰利他赛普治疗系统性红斑狼疮(SLE)的临床疗效和安全性。方法本回顾性单中心观察研究纳入了41例在2021年4月至2022年3月期间接受泰利他塞普治疗的SLE患者。收集基线特征和24周随访临床结果进行分析。结果共纳入41例至少接受过一次泰利他赛的SLE患者。与基线(10.0±6.85)相比,SLEDAI-2K评分在12周(6.25±5.46,p < .001)和24周(4.18±4.78,p < .001)显著降低。根据SLEDAI-2K评估,器官受累的比例在皮肤/粘膜和肌肉骨骼受累中显著降低。与基线(20.87±16.71 mg/d)相比,12周(14.19±8.88 mg/d, p < 0.001)和24周(9.86±4.25 mg/d, p = 0.001)的平均糖皮质激素剂量(相当于强的松)显著降低。C3和C4水平呈上升趋势。狼疮性肾炎患者24小时尿蛋白水平从基线时的2.81±3.83 g/天显著降低到治疗24周后的1.00±1.32 g/天(p = 0.005),降幅为68.66% (IQR, 35.61%, 76.30%)。白蛋白水平也显著提高(p = 0.003)。6例患者出现9例治疗不良事件(teae),均为轻度和中度。结论在现实世界的研究中,泰利他赛普联合常规疗法治疗SLE患者具有良好的起病疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.

Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.

Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.

Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.

ObjectivesTo assess the real-world efficacy and safety of telitacicept in Chinese systemic lupus erythematosus (SLE) patients.MethodsThis retrospective single-center observational study enrolled 41 SLE patients treated with telitacicept between April 2021 and March 2022. Baseline characteristics and 24-week follow-up clinical outcomes were collected for analysis.ResultsA total of 41 SLE patients who received telitacicept at least once were included. Compared with baseline (10.0 ± 6.85), SLEDAI-2K scores significantly decreased at 12 weeks (6.25 ± 5.46, p < .001) and 24 weeks (4.18 ± 4.78, p < .001). The proportion of organ involvement, as assessed by SLEDAI-2K, significantly decreased in skin/mucosa and musculoskeletal involvement. The mean glucocorticoid dose (prednisone equivalent) was significantly reduced at 12 weeks (14.19 ± 8.88 mg/d, p < .001) and 24 weeks (9.86 ± 4.25 mg/d, p = .001) compared with baseline (20.87 ± 16.71 mg/d). C3 and C4 levels showed an increasing trend. In patients with lupus nephritis, 24-h urinary protein levels significantly reduced from 2.81 ± 3.83 g/day at baseline to 1.00 ± 1.32 g/day after 24 weeks of treatment (p = .005), with a 68.66% decline (IQR, 35.61%, 76.30%). Albumin levels also significantly improved (p = .003). Nine treatment-emergent adverse events (TEAEs) were recorded in six patients, all of which were mild and moderate.ConclusionsIn this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lupus
Lupus 医学-风湿病学
CiteScore
4.20
自引率
11.50%
发文量
225
审稿时长
1 months
期刊介绍: The only fully peer reviewed international journal devoted exclusively to lupus (and related disease) research. Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines. Invaluable reading, with extended coverage, lupus-related disciplines include: Rheumatology, Dermatology, Immunology, Obstetrics, Psychiatry and Cardiovascular Research…
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信